ESTRELLA IMMUNOPHARMA, INC. (ESLAW) Operating cash flow 2021–2025
ESTRELLA IMMUNOPHARMA, INC. (ESLAW) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$1.8MFY2025 · since FY2021: -$316,158 → -$1.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$1.8M | — |
| FY2023 | -$16.1M | -1102.6% |
| FY2022 | -$1.3M | -322.6% |
| FY2021 | -$316,158 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ESLAW financial trends
ESLAW RevenueESLAW Net incomeESLAW Net marginESLAW Gross profitESLAW Gross marginESLAW Operating incomeESLAW Operating marginESLAW Free cash flowESLAW Capital expendituresESLAW Return on equityESLAW Stock buybacksESLAW Dividends paidESLAW Total assetsESLAW Total liabilitiesESLAW Shareholders’ equityESLAW overview →